For the quarter ending 2025-09-30, STRO made $9,693K in revenue. -$56,857K in net income. Net profit margin of -586.58%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 9,693 | 63,745 | 17,399 | 8,520 |
| Research and development | 39,853 | 38,325 | - | 62,108 |
| General and administrative | 8,741 | 10,343 | - | 14,331 |
| Restructuring and related costs | 9,558 | 18,422 | - | - |
| Total operating expenses | 58,152 | 67,090 | 85,913 | 76,439 |
| Loss from operations | -48,459 | -3,345 | -68,514 | -67,919 |
| Interest income | 2,009 | 2,519 | 3,189 | 4,875 |
| Unrealized gain on equity securities | - | 0 | - | - |
| Non-cash interest expense related to the sale of future royalties | 9,670 | 9,647 | 9,344 | 7,910 |
| Interest and other income (expense), net | -737 | -1,044 | -1,299 | 22,167 |
| Loss before provision for income taxes | -56,857 | -11,517 | - | -48,787 |
| (benefit) from / provision for income taxes | 0 | -18 | - | - |
| Net loss | -56,857 | -11,499 | -75,968 | -48,787 |
| Net loss per share, basic | -0.67 | -0.14 | -0.91 | -0.59 |
| Net loss per share, diluted | -0.67 | -0.14 | -0.91 | -0.59 |
| Weighted average number of shares outstanding, basic, total | 84,869,864 | 84,580,125 | 83,106,013 | 82,043,671 |
| Weighted-average shares used to compute diluted eps | 84,869,864 | 84,580,125 | 83,106,013 | 82,043,671 |
SUTRO BIOPHARMA, INC. (STRO)
SUTRO BIOPHARMA, INC. (STRO)